Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.3%

14 terminated/withdrawn out of 124 trials

Success Rate

81.6%

-5.0% vs industry average

Late-Stage Pipeline

13%

16 trials in Phase 3/4

Results Transparency

2%

1 of 62 completed trials have results

Key Signals

36 recruiting1 with results10 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
58(55.2%)
Phase 2
22(21.0%)
Phase 3
9(8.6%)
Phase 1
9(8.6%)
Phase 4
7(6.7%)
105Total
N/A(58)
Phase 2(22)
Phase 3(9)
Phase 1(9)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (124)

Showing 20 of 124 trials
NCT07663994Not ApplicableRecruiting

Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort

Role: lead

NCT06876532Not ApplicableRecruiting

Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

Role: lead

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: lead

NCT03986437Completed

A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.

Role: lead

NCT00209989Phase 2Completed

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Role: lead

NCT02856347Not ApplicableCompleted

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

Role: lead

NCT06589414Not ApplicableCompleted

Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study

Role: lead

NCT03514368Not ApplicableRecruiting

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

Role: lead

NCT06797037Not ApplicableRecruiting

Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)

Role: lead

NCT06517355Recruiting

Acceptability and Benefits of an Onco-sexology Program for Laryngectomy Patients and Their Partners

Role: lead

NCT06967961Not ApplicableRecruiting

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Role: lead

NCT06219187Completed

Male breAsT cAncer preDisposition Factor

Role: lead

NCT05151718Recruiting

Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents

Role: lead

NCT06022159Phase 2Recruiting

A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

Role: lead

NCT06904625Not ApplicableRecruiting

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

Role: lead

NCT03627988Phase 2Completed

Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.

Role: lead

NCT00210041Phase 2Completed

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Role: lead

NCT05826509Phase 2Active Not Recruiting

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

Role: lead

NCT07195344Phase 4Recruiting

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Role: lead

NCT07558343Not ApplicableNot Yet Recruiting

Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2

Role: lead